Refine by
In Vivo Antiedematogenic Activity Equipment & Supplies
79 equipment items found
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
SL-801 is a structurally novel, oral, small molecule, reversible inhibitor of exportin-1 (XPO1), a nuclear transport protein implicated in both solid tumors and hematologic malignancies. SL-801 has demonstrated preclinical in vitro and in vivo antitumor activity against a wide array of solid and hematologic cancers. SL-801’s potential ability to reversibly bind XPO1 may offer the ...
Manufactured by:Labeo Technologies Inc. based inMontreal, QUEBEC (CANADA)
The Fiber Photometry System by Labeo Technologies Inc. is designed for comprehensive in vivo studies of brain activity in freely moving rodents, including mice and rats. It provides precise measurements essential for neuroscience research, accommodating various applications such as imaging calcium indicators and utilizing FRET for high sensitivity in ratiometric biosensors. The system includes a ...
Manufactured by:Stasys Medical Corporation based inSeattle, WASHINGTON (USA)
The system is designed to form microclots from whole blood samples to measure platelet forces, aggregation, and function. No use of agonists or reagents, no offsite labs; faster, more accurate results means faster, more-informed decision-making for trauma doctors. ...
Manufactured by:TargetMol Chemicals Inc. based inWellesley Hills, MASSACHUSETTS (USA)
RMC-9805 is a novel, mutant-selective, covalent and oral KRASG12D (ON) inhibitor. A stable and high affinity triple complex is formed between RMC-9805, KRASG12D, and cyclophilin A, which inhibits signal transduction downstream of KRASG12D (ON) by disrupting its interaction with downstream effectors. RMC-9805 can induce cell apoptosis and promote tumor regression in preclinical KRASG12D tumor ...
Manufactured by:Cabaletta Bio, Inc. based inPhiladelphia, PENNSYLVANIA (USA)
Precision Approach to Address the Underlying Cause of Disease: Our second candidate, MuSK-CAART, is designed to treat myasthenia gravis (MG), an autoimmune disease affecting the neuromuscular junction that can lead to motor impairment, muscle weakness, and respiratory ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
CHM 1101 (CLTX CAR T) is an optimized first-in-class CAR T cell therapy that uniquely utilizes Chlorotoxin (CLTX), a 36-amino acid peptide derived from deathstalker scorpion venom as its tumour targeting ...
by:Aphios Corporation based inWoburn, MASSACHUSETTS (USA)
APH-0912 is a combination of a Taxotere® prodrug and monoclonal antibody targeted to treat metastatic cancer. The prodrug is a combination of a docetaxel molecule, the potent anticancer drug, and a sugar molecule to enhance solubility covalently linked to a tumor-specific antibody. This molecular combination is not bioactive prior to administration. After infusion and adsorption onto targeted ...
Manufactured by:Elpiscience based inShanghai, CHINA
ES002’s dual ATP-adenosine mechanism is a potentially powerful TME regulator and transformative cancer immunotherapy. In preclinical studies ES002 demonstrated significant single agent anti-tumor activity as well as an excellent tolerability profile. ES002 has also shown superior enzymatic inhibition and binding ...
Manufactured by:Elpiscience based inShanghai, CHINA
ES014 is a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb) that simultaneously targets the adenosine and TGF-β pathways, two major immunosuppressive mechanisms in the tumor microenvironment (TME). Solid tumors frequently express TGF-β, which suppresses T cell activation and induces CD39 expression, the rate-limiting enzyme in the ATP-adenosine pathway. The anti-CD39 ...
Manufactured by:Mersana Therapeutics based inCambridge, MASSACHUSETTS (USA)
ADCs are not one-size-fits-all. The Dolasynthen platform enables an iterative approach to develop the right ADC for a given indication through customization and optimization. Dolasynthen utilizes a synthetic scaffold for precise control of DAR (from 2-24) and site-specific antibody bioconjugation. The platform is also able to homogeneously generate ADCs with precisely defined DARs for consistent ...
by:Aphios Corporation based inWoburn, MASSACHUSETTS (USA)
Poor Solubility and Associated Formulation and Bioavailability Difficulties. Although paclitaxel is an effective anticancer drug, its solubility is low (~ 0.4 µg/mL), which limits its medical utility to intravenous applications. Docetaxel (Taxotere®) was developed as a paclitaxel derivative having improved water solubility; its solubility, however, is only ~ 14 µg/mL. Several ...
Manufactured by:Qualigen Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
Our RAS-F portfolio includes lead and back-up small molecules that suppress the interaction of endogenous RAS with c-RAF, upstream of the KRAS, HRAS, and NRAS effector pathways. This potentially enables a differentiated, RAS-targeted strategy for inhibiting the MAPK, PI3K, and TOR pathways that are implicated in cancer cell proliferation, survival, and differentiation (see figure). RAS itself ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
AR-C102222 hydrochloride is a potent, competitive, orally active and highly selective inducible nitric oxide synthase (iNOS) inhibitor, with an IC50 of 37 nM[1]. AR-C102222 hydrochloride has antinociception and anti-inflammatory ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
APD668 is a potent, selective and orally active agonist of G-protein coupled receptor GPR119, with EC50s of 2.7 nM and 33 nM for hGPR119 and rGPR119, respectively. APD668 shows no significant inhibition of any of the five major CYP isoforms with the exception of CYP2C9 (Ki=0.1 μM). APD668 can be used for the research of steatohepatitis and ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Azathioprine (BW 57-322) is an orally active immunosuppressive agent. Azathioprine can be converted in vivo to the active metabolite 6-mercaptopurine (6-MP). Azathioprine has myelosuppressive effects and induces ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Flurocitabine (5-Fluorocyclocytidine) is a fluorinated anlydride analog of cytosine arabinoside, partially hydrolysecl in vivo into two active antitumor substances (arabinosyl-tluorocytosine (ara-FC) and arabinosyl-fluorouracil (ara-FU)). Flurocitabine (5-Fluorocyclocytidine) has antitumor activity during phase I studies in acute leukemia and solid ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
cRIPGBM chloride, an orally active, proapoptotic derivative. cRIPGBM can be generated from glioblastoma multiforme (GBM) cancer stem cells (CSCs). cRIPGBM(chloride) targets to receptor-interacting protein kinase 2 (RIPK2) to induce caspase 1-dependent apoptosis. cRIPGBM(chloride) suppresses the formation of RIPK2/TAK1 (prosurvival complex), and increases the formation of RIPK2/caspase 1 ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
AMG-337 is a potent, orally active, selective MET kinase inhibitor with IC50 values of 1, 1, 4.7, 5, 21.5, 1077 and >4000 nM of WT MET, H1094R MET, M1250T MET, HGF-stimulated pMET (PC3 cells) MET, V1092I MET, Y1230H MET, and D1228H MET, respectively. AMG 337 inhibits the phosphorylation of MET and downstream effectors in MET-amplified cancer cell lines, resulting in an inhibition of MET-dependent ...